Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects

Archives of Cardiovascular Diseases

Volumn 106, Issue 10, 2013, Pages 517-527

  Mao, Liu ^a   Jian, Chen ^a   Changzhi, Liu ^a   Dan, Huang ^a   Suihua, Huang ^a   Wenyi, Tang ^a   Wei, Wu ^a  

^a THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Clopidogrel; Coronary artery disease; CYP2C19; Meta analysis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19;

ADVERSE CLINICAL EVENT; ADVERSE OUTCOME; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CORONARY ARTERY DISEASE; DRUG SAFETY; FOLLOW UP; GENE FREQUENCY; GENETIC RISK; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HETEROZYGOTE; HUMAN; LOADING DRUG DOSE; META ANALYSIS; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS;

ACS; ACUTE CORONARY SYNDROME; CAD; CI; CLOPIDOGREL; CONFIDENCE INTERVAL; CORONARY ARTERY DISEASE; CYP; CYP2C19; CYTOCHROME P450; MALADIE CORONAIRE; META-ANALYSIS; MÉTA-ANALYSE; MI; MYOCARDIAL INFARCTION; ODDS RATIO; OR; PCI; PCR; PERCUTANEOUS CORONARY INTERVENTION; POLYMERASE CHAIN REACTION; ST; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; TARGET VESSEL REVASCULARIZATION; TLR; TVR;

ARYL HYDROCARBON HYDROXYLASES; CHI-SQUARE DISTRIBUTION; CORONARY THROMBOSIS; DRUG RESISTANCE; GENOTYPE; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PHENOTYPE; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; STENTS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84886447002     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2013.06.055     Document Type: Article

References (52)

1. S.B. King 3rd, S.C. Smith Jr., and J.W. Hirshfeld Jr. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines J Am Coll Cardiol 51 2008 172 209
2. P. Savi, and J.M. Herbert Clopidogrel ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis Semin Thromb Hemost 31 2005 174 183
3. E.I. Lev, R.T. Patel, and K.J. Maresh Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance J Am Coll Cardiol 47 2006 27 33
4. I. Muller, F. Besta, and C. Schulz Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement Thromb Haemost 89 2003 783 787
5. T.A. Nguyen, J.G. Diodati, and C. Pharand Resistance to clopidogrel: a review of the evidence J Am Coll Cardiol 45 2005 1157 1164
6. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives J Am Coll Cardiol 49 2007 1505 1516
7. S. Matetzky, B. Shenkman, and V. Guetta Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
8. F. Sofi, R. Marcucci, and A.M. Gori Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis Thromb Haemost 103 2010 841 848
9. D.J. Angiolillo, A. Fernandez-Ortiz, and E. Bernardo Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel Arterioscler Thromb Vasc Biol 26 2006 1895 1900
10. C. Frere, T. Cuisset, and B. Gaborit The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome J Thromb Haemost 7 2009 1409 1411
11. J.T. Brandt, S.L. Close, and S.J. Iturria Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel J Thromb Haemost 5 2007 2429 2436
12. K.A. Kim, P.W. Park, and S.J. Hong The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance Clin Pharmacol Ther 84 2008 236 242
13. K. Yamamoto, S. Hokimoto, and T. Chitose Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during anti-platelet therapy J Cardiol 57 2011 194 201
14. A. Akhlaghi, S. Shirani, and N. Ziaie Cytochrome P450 2C19 polymorphism in Iranian patients with coronary artery disease ARYA Atheroscler 7 2011 106 110
15. H.J. Bouman, E. Schomig, and J.W. van Werkum Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 2011 110 116
16. S.J. Hwang, Y.H. Jeong, and I.S. Kim The cytochrome 2C19*2 and*3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention Thromb Res 127 2011 23 28
17. L.A. Malek, J. Przyluski, and M. Spiewak Cytochrome P450 2C19 polymorphism, suboptimal reperfusion and all-cause mortality in patients with acute myocardial infarction Cardiology 117 2010 81 87
18. R. Nishio, T. Shinke, and H. Otake Effect of cytochrome P450 2C19 polymorphism on target lesion outcome after drug-eluting stent implantation in japanese patients receiving clopidogrel Circ J 76 2012 2348 2355
19. I.Y. Oh, K.W. Park, and S.H. Kang Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents Heart 98 2012 139 144
20. Y. Peng, M. Chen, and X.J. Liu The CYP2C19 genotype does not impact the long-term prognosis of patients with coronary artery disease Atherosclerosis 227 2013 106 111
21. T. Simon, C. Verstuyft, and M. Mary-Krause Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
22. X.F. Tang, J. Wang, and J.H. Zhang Effect of the CYP2C19 2 and 3 genotypes ABCB1 C3435 T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention Eur J Clin Pharmacol 69 2013 1103 1112
23. G. Wells, D. Beaton, and B. Shea Minimal clinically important differences: review of methods J Rheumatol 28 2001 406 412
24. G.A. Wells, B. Shea, and D. O'Connell The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2013 [Available at: http://www.ohri.ca/PROGRAMS/CLINICAL-EPIDEMIOLOGY/OXFORD.ASP (accessed 12 Feb. 2013)]
25. Y. Luo, Y.T. Zhao, and A. Verdo Relationship between cytochrome P450 2C19*2 polymorphism and stent thrombosis following percutaneous coronary intervention in Chinese patients receiving clopidogrel J Int Med Res 39 2011 2012 2019
26. T. Sawada, T. Shinke, and J. Shite Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel Circ J 75 2011 99 105
27. X.F. Tang, C. He, and J.Q. Yuan Impact of cytochrome P450 2C19 polymorphisms on outcome of cardiovascular events in clopidogrel-treated Chinese patients after percutaneous coronary intervention Zhonghua Xin Xue Guan Bing Za Zhi 39 2011 617 620
28. J.P. Collet, J.S. Hulot, and A. Pena Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
29. B. Giusti, A.M. Gori, and R. Marcucci Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis Am J Cardiol 103 2009 806 811
30. A.M. Harmsze, J.W. van Werkum, and J.M. Ten Berg CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study Eur Heart J 31 2010 3046 3053
31. L.A. Malek, B. Kisiel, and M. Spiewak Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel Circ J 72 2008 1165 1169
32. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
33. G. Pare, S.R. Mehta, and S. Yusuf Effects of CYP2C19 genotype on outcomes of clopidogrel treatment N Engl J Med 363 2010 1704 1714
34. A.R. Shuldiner, J.R. O'Connell, and K.P. Bliden Association of cytochrome P450 2C19 genotype with the anti-platelet effect and clinical efficacy of clopidogrel therapy JAMA 302 2009 849 857
35. D. Sibbing, J. Stegherr, and W. Latz Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention Eur Heart J 30 2009 916 922
36. K.A. Tiroch, D. Sibbing, and W. Koch Protective effect of the CYP2C19*17 polymorphism with increased activation of clopidogrel on cardiovascular events Am Heart J 160 2010 506 512
37. D. Trenk, W. Hochholzer, and M.F. Fromm Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents J Am Coll Cardiol 51 2008 1925 1934
38. L. Wallentin, S. James, and R.F. Storey Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial Lancet 376 2010 1320 1328
39. A.Y. Gasparyan, T. Watson, and G.Y. Lip The role of aspirin in cardiovascular prevention: implications of aspirin resistance J Am Coll Cardiol 51 2008 1829 1843
40. Z. Desta, X. Zhao, and J.G. Shin Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 2002 913 958
41. J.S. Jang, K.I. Cho, and H.Y. Jin Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel Am J Cardiol 110 2012 502 508
42. M. Zabalza, I. Subirana, and J. Sala Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel Heart 98 2012 100 108
43. B. Jin, H.C. Ni, and W. Shen Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel Mol Biol Rep 38 2011 1697 1702
44. J.S. Hulot, J.P. Collet, and J. Silvain Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis J Am Coll Cardiol 56 2010 134 143
45. D.R. Holmes Jr., G.J. Dehmer, and S. Kaul ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association Circulation 122 2010 537 557
46. C. Auffray, D. Charron, and L. Hood Predictive, preventive, personalized and participatory medicine: back to the future Genome Med 2 2010 57
47. T. Cuisset, G. Cayla, and J. Silvain Clopidogrel resistance: what's new? Arch Cardiovasc Dis 103 2010 349 353
48. H. Jneid, J.L. Anderson, and R.S. Wright 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 60 2012 645 681
49. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes Circulation 119 2009 2553 2560
50. C. Varenhorst, S. James, and D. Erlinge Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease Eur Heart J 30 2009 1744 1752
51. C.P. Cannon, S. Husted, and R.A. Harrington Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate-receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial J Am Coll Cardiol 50 2007 1844 1851
52. L.B. Gerson Proton pump inhibitors and potential interactions with clopidogrel: an update Curr Gastroenterol Rep 15 2013 329